OIS at AAO 2015

GenSight Biologics

Nov 12, 2015 11:01am ‐ Nov 12, 2015 11:09am


GenSight Biologics is a clinical-stage biotechnology company developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and afterwards of the central nervous system. GenSight’s pipeline leverages two core technology platforms, mitochondrial targeting sequence and optogenetics, to help preserve or restore vision in patients with severe retinal diseases.


You must be logged in and own this session in order to post comments.